Anteris Technologies Global Corp. (AVR) carries a Roarable Rating of E (Strong Sell) with 23/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
As of 2026-11-02, Anteris Technologies Global Corp. (NASDAQ: AVR) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 23/100 at a spot price of $6.31 (-1.71% 1D, market cap $625.9M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 5/20, Executive Insider Alignment 5/20, FRED Macro Regime Fit 3/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, AVR ranks #961 in composite RQD confidence.
Within the Health Care sector (Industrial Specialties), AVR carries a Roarable E (23/100 RQD), trailing P/E of N/A, gross margin of 70.3%, and ROIC of -35.0%. By comparison, SMTI (Sanara MedTech Inc.) holds a D+ grade (55/100 RQD, P/E 8.1x, ROIC 16.3%, cap $302.4M) and ENOV (Enovis Corporation) posts a D grade (44/100 RQD, P/E N/A, ROIC -32.7%, cap $1.32B). Among the 5-stock peer group, SMTI leads on earnings multiple (8.1x) while SMTI leads on capital efficiency (16.3% ROIC).
Per AVR's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0002011514), Anteris Technologies Global Corp. generated $1.9M in revenue (-29.2% YoY), -$94.1M in net income, and -$79.8M in free cash flow against $23.0M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 70.3% Gross Margin
20D Institutional Volume Accumulation (±10.6% realized swing band)
Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
While AVR currently carries a cautious 23/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Health Care with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($7.50) and Max Pain ($6.63) forces dealer call-delta covering toward $11.61.
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
Anteris Technologies Global Corp. (AVR) slipped -1.71% to $6.31, trading at 39% of its 52-week range ($3.3 – $11.06). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
Yahoo Finance report covering Anteris Technologies Global Corp. (AVR) market action, institutional positioning, and fundamental catalysts.
TradingView report covering Anteris Technologies Global Corp. (AVR) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering Anteris Technologies Global Corp. (AVR) market action, institutional positioning, and fundamental catalysts.
Investing.com UK report covering Anteris Technologies Global Corp. (AVR) market action, institutional positioning, and fundamental catalysts.
Kalkine report covering Anteris Technologies Global Corp. (AVR) market action, institutional positioning, and fundamental catalysts.
TradingView report covering Anteris Technologies Global Corp. (AVR) market action, institutional positioning, and fundamental catalysts.
kalkine.ca report covering Anteris Technologies Global Corp. (AVR) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance report covering Anteris Technologies Global Corp. (AVR) market action, institutional positioning, and fundamental catalysts.
Anteris Technologies Pty Ltd (ASX:AVR, NASDAQ:AVR) has reported encouraging 30-day clinical and haemodynamic results for the medium-size DurAVR transcatheter heart valve (THV), including low pressure gradients, large val
The S&P/ASX Small Ordinaries Index (AXS: XSO) ended Friday at 3,147.90 points, down 23.50 points or 0.74%. Despite the weaker session, the small-cap benchmark remained higher over the week, gaining 92.50 points or 3.03%
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. -29.2% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on AVR today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for AVR. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, Anteris Technologies Global Corp. (AVR) ranks #961 by composite RQD confidence (23/100, grade E) and #416 by equity capitalization ($625.9M). Within this direct 5-issuer industry benchmark cohort, SMTI leads on earnings valuation at 8.1x trailing P/E, while SMTI leads on capital efficiency and profitability with 16.3% ROIC and 92.7% gross margin. CDRE currently holds the highest overall quantitative score in the immediate peer group at 62/100 (C) compared with AVR at 23/100 (E).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| AVR
ACTIVE
Anteris Technologies Global Corp. | E | 23/100 | — | 70.3% | -35.0% | -1.71% | $625.9M | Benchmark Subject |
| SMTI Sanara MedTech Inc. | D+ | 55/100 | 8.1x | 92.7% | 16.3% | -0.26% | $302.4M | /smti-vs-avr → |
| ENOV Enovis Corporation | D | 44/100 | — | 59.8% | -32.7% | -12.71% | $1.32B | /enov-vs-avr → |
| ZJYL JIN MEDICAL INTERNATIONAL LTD. (Class A) | D- | 36/100 | — | 29.2% | — | +26.34% | $294.2M | /zjyl-vs-avr → |
| CDRE Cadre Holdings Inc. | C | 62/100 | 30.2x | 42.5% | 11.0% | -2.38% | $1.33B | /cdre-vs-avr → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), Anteris Technologies Global Corp. (AVR) reported GAAP revenue of $1.9M (-29.2% vs. FY2024 revenue of $2.7M ) , GAAP net income of -$94.1M, operating cash flow of -$77.8M, and free cash flow of -$79.8M (-25.6% YoY). On the balance sheet, AVR closed FY2025 with $23.0M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $1.9M | -$94.1M | -$77.8M | -$79.8M | $23.0M | — |
| FY2024 (FY) | 2024-12-31 | $2.7M | -$76.3M | -$61.2M | -$63.5M | $80.7M | — |
As of 2026-11-02, Anteris Technologies Global Corp. (NASDAQ: AVR) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 23/100 at a spot price of $6.31 (-1.71% 1D, market cap $625.9M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 5/20, Executive Insider Alignment 5/20, FRED Macro Regime Fit 3/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, AVR ranks #961 in composite RQD confidence.
Within the Health Care sector (Industrial Specialties), AVR carries a Roarable E (23/100 RQD), trailing P/E of N/A, gross margin of 70.3%, and ROIC of -35.0%. By comparison, SMTI (Sanara MedTech Inc.) holds a D+ grade (55/100 RQD, P/E 8.1x, ROIC 16.3%, cap $302.4M) and ENOV (Enovis Corporation) posts a D grade (44/100 RQD, P/E N/A, ROIC -32.7%, cap $1.32B). Among the 5-stock peer group, SMTI leads on earnings multiple (8.1x) while SMTI leads on capital efficiency (16.3% ROIC).
Per AVR's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0002011514), Anteris Technologies Global Corp. generated $1.9M in revenue (-29.2% YoY), -$94.1M in net income, and -$79.8M in free cash flow against $23.0M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
AVR last traded at $6.31 (-1.71% on volume of 1,396,960 shares), positioning the stock -15.87% below its 50-day simple moving average ($7.50) and -14.73% below its 200-day simple moving average ($7.40). Across its 52-week range of $3.30 to $11.06, AVR sits at the 38.8% percentile with a 14-day RSI of 44.1 (NEUTRAL RANGE) and an implied next-earnings move of ±10.6% ($5.64 to $6.98).
Why AVR Stock slipped -1.71% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
Per the Roarable RQD rating, AVR scores 23 out of 100 with a letter grade of E, labeled "Roarable Strong Sell — Forensic Risk / Avoid." The five pillars are: Fundamental Cash Engine at 7/20 (ROIC -35%; FCF yield -12.74%), Whale 13F Flow at 5/20 (institutional accumulation and options positioning), Insider Conviction at 3/20 (SEC Form 4 and Congressional PTR cluster flow), Macro Regime Fit at 3/20 (Beta 1.0; sector sensitivity), and Forensic Balance Sheet at 5/20 (Altman Z 2.5; Piotroski F 2/9; Debt/Equity 0.5). Every pillar sits well below half of its maximum, with the cash engine and insider signals weakest in relative terms. For a prospective investor, the practical implication is that the rating reflects negative cash generation and weak forensic scores rather than a single isolated flaw. A reader weighing upside should note that the rating's own framing is negative on fundamentals, and that the price move on the reporting date (+5.25%) is not by itself evidence that the underlying cash engine has improved. Valuation tradeoffs cannot be assessed on earnings multiples because P/E and EPS are not available in source data; the investment case therefore rests on balance-sheet durability and the trajectory of cash burn, both of which the source data shows moving unfavorably. This is an analytical framing, not personalized advice.
Anteris Technologies Global Corp. (AVR) is a NASDAQ-listed issuer classified under the Health Care sector and Industrial Specialties industry. The source profile does not describe its specific products, customers, or revenue model. Reported revenue of $1.9M for FY 2025 and $2.7M for FY 2024 indicates a very small revenue base relative to its operating losses. Gross margin is reported at 70.3%.
| Period | Revenue | Operating Income | Net Income | EPS | FCF | Cash | Debt |
|---|---|---|---|---|---|---|---|
| FY 2025 | $1.9M | $-93.9M | $-94.1M | N/A | $-79.8M | $6.7M | N/A |
| FY 2024 | $2.7M | $-78.4M | $-76.3M | N/A | $-63.5M | $70.5M | N/A |
Per the SEC financials, operating margin and net margin are each reported at -60%, and ROIC is -35%. Revenue declined from $2.7M to $1.9M while operating loss widened from $-78.4M to $-93.9M and cash fell from $70.5M to $6.7M. Per the Roarable RQD rating, the Altman Z-Score is 2.5, the Piotroski F-Score is 2 out of 9, and Debt/Equity is 0.5, with the forensic balance-sheet pillar scoring 5/20. Debt figures are not available in source data, so the Debt/Equity ratio cannot be independently reconciled to reported debt.
The Butterfly supply-chain graph reports no supply-chain links and no proprietary signals, so no supply-chain catalysts are recorded.
Per the Butterfly Supply-Chain Graph, supply chain is recorded as NONE, with no butterfly links and no proprietary signals. The source data therefore does not identify upstream suppliers, downstream customers, or sector correlations for AVR. Investors should note that the absence of recorded links is a data limitation, not evidence of independence. The second-order risk the data does make visible is funding-related: with FY 2025 cash at $6.7M against a $-79.8M free cash flow outflow, the company's ability to sustain operations without new capital is a central bottleneck, and any dilution or financing event would be a ripple to watch.
Analyst data is not available in source data. Holder data is not available in source data. The only analyst-related items are the headlines referenced above: a price target cut to $12.84 (TradingView) and a reiterated Overweight rating from Cantor Fitzgerald (Investing.com UK). Per the Roarable RQD rating, institutional accumulation and options positioning scores 5/20 and insider conviction scores 3/20, reflecting SEC Form 4 and Congressional PTR cluster flow, but no individual 13F or Form 4 transaction records are provided in the holders section.
Real-time company headlines, analyst actions, and sector developments for Anteris Technologies Global Corp. (AVR) • Click "Debate This Headline" to argue it in the Roar Pit below
Yahoo Finance report covering Anteris Technologies Global Corp. (AVR) market action, institutional positioning, and fundamental catalysts.
TradingView report covering Anteris Technologies Global Corp. (AVR) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering Anteris Technologies Global Corp. (AVR) market action, institutional positioning, and fundamental catalysts.
Investing.com UK report covering Anteris Technologies Global Corp. (AVR) market action, institutional positioning, and fundamental catalysts.
Kalkine report covering Anteris Technologies Global Corp. (AVR) market action, institutional positioning, and fundamental catalysts.
TradingView report covering Anteris Technologies Global Corp. (AVR) market action, institutional positioning, and fundamental catalysts.
kalkine.ca report covering Anteris Technologies Global Corp. (AVR) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance report covering Anteris Technologies Global Corp. (AVR) market action, institutional positioning, and fundamental catalysts.
Welcome to the AVR (Anteris Technologies Global Corp.) Roar Pit. Current RQD Composite is 23/100 (Roarable Strong Sell — Forensic Risk / Avoid) in Industrial Specialties. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.
Everyone in here is repeating the bull case on AVR, but look at what you are paying: current EV/EBITDA multiples with 70.3% gross margins. Unless Anteris Technologies Global Corp. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.
Looking at the 5-pillar RQD breakdown on AVR, the market is fixating on short-term headline noise in Industrial Specialties and ignoring the balance sheet and cash flow trajectory. At $6.42 (52-wk range $3.30 - $11.06), any beat on forward guidance forces shorts and underweight funds to chase.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Devon Kess, Gideon Vane, Eliott Vance, Sorel Thorne, Corin Hale, Tessa Rane, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your Google email below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Virtual Cash Arena account (100% free — no credit card required).